Q2 Solutions Q2 Solutions Actionable Insights for Better Health and Lab Solutions
Refine Results

Each year, researchers and clinicians renew their determination to make a difference in the diagnosis and treatment of cancer on World Cancer Day.  This year’s campaign theme is “We can. I can.”—an appropriate slogan for a fight that truly does depend on everyone’s contribution. Each person, from donors and patients to scientists and doctors, has a role to play in reducing the global burden of cancer. At Q2 Solutions, we’re attacking cancer from many angles, but one approach we’re particularly excited about is the use of anatomic pathology for biomarker development in clinical trials. This technology can help predict and assess how a patient will respond to immune-oncology (IO) therapies... Read More

Topics

Biomarkers , End-to-End Services

Diabetes is fast becoming a global healthcare epidemic. The number of people with diabetes rose from 108 million in 1980 to 422 million in 2014, with related deaths projected to rise by more than 50 percent in the next 10 years (http://www.who.int/mediacentre/factsheets/fs312/en/).  Lack of awareness and access to proper treatment can also lead to serious complications, such as blindness, amputation and kidney failure. And while the healthcare industry is effective at managing diabetes as a disease, physicians and patients could be doing more to test for early warning signs that indicate that these complications are emerging.  The need for early diagnosis and better monitoring is the... Read More

Topics

Clinical Trials

Today’s complex clinical trials need the support of a laboratory that can provide scientific, technological, and operational expertise to better meet the needs of patients, sites, and the sponsors they support. Costa Panagos, CEO Q2 Solutions Today’s drug development pipeline includes many new and exciting opportunities – from precision medicine approaches to complex targeted therapies, compounds and drug-specific companion diagnostics.  To improve the probability of success for this pipeline, collaborative teams with a wide range of expertise are required. The days when a single biopharmaceutical company might develop an oncology drug from preclinical research through market delivery are... Read More

Topics

Central Laboratories , Clinical Trials , End-to-End Services